HOME Research Insight Cardinal Health, Inc. (U.S.) and Mallinckrodt plc (Ireland) have Secured the Leadership Position in the Global Nuclear Medicine/Radiopharmaceuticals Market



Cardinal Health, Inc. (U.S.) and Mallinckrodt plc (Ireland) have Secured the Leadership Position in the Global Nuclear Medicine/Radiopharmaceuticals Market


Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90), & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

A number of key players are competing against each other in order to expand their existing customer base in the nuclear medicine/radiopharmaceuticals market. The top five players accounted for ~55% of the total nuclear medicine/radiopharmaceuticals market in 2015. These key players include Cardinal Health, Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.S.), Bayer AG (Germany), and Lantheus Medical Imaging, Inc. (U.S.). Other players in this market include Eckert & Ziegler Radiopharma GmbH (Germany), Advanced Accelerator Applications S.A. (France), and Jubilant Life Sciences Ltd. (India).

Cardinal Health was the leading player in the nuclear medicine/radiopharmaceuticals market, holding 25% of the market share in 2015. Through its pharmaceutical segment, the company offers diagnostic radioisotopes such as Technetium-99m Sestamibi and Iodine I-123 sodium iodide capsules. The company also undertakes contract manufacturing of radiopharmaceutical products such as Xofigo (Ra-223 Chloride) for Bayer AG in the U.S. and Canada. The company primarily focuses on inorganic growth strategies such as agreements, collaborations, and partnerships for increasing its share in the market. In June 2016, Cardinal Health and Advanced Accelerator Applications S.A. (AAA) (France) entered into an agreement for the production of AAA’s NETSPOT. Cardinal Health’s extensive U.S. network of radiopharmaceutical manufacturing facilities will prepare and deliver NETSPOT patient doses to advanced medical imaging sites. The company has gained a major share in the nuclear medicine/radiopharmaceuticals market on account of its comprehensive product portfolio, and wide geographical reach as well as focus on organic growth strategies.

Mallinckrodt plc is another leading player in the nuclear medicine/radiopharmaceuticals market, holding 10% of the market in 2014. The company offers its products through its nuclear imaging segment namely which includes Octreoscan, Tc-99m Sestamibi, Thallous Chloride TI 201 Injection, Ultratag RBC, Technescan MAG3, Gallium Citrate Ga 67 Injection, Indium In-111 Chloride Sterile Solution, Sodium Iodide I-123 Capsules, Technescan HDP, Technescan PYP, and Ultratag RBC for the SPECT diagnostic market and Sodium Iodide I-131 Therapeutic Capsules for oral use. The company focuses on new product development to strengthen its product offering in the market. This strategy is strongly backed by its R&D investments, which were USD 185.1 million in 2015, USD 165.7 million in 2014, and USD 144.1 million in 2013, respectively.

Players operating in the nuclear medicine/radiopharmaceuticals market adopted the strategy of agreements, partnerships, and contracts (35.6% of the total strategic developments in the market during 2013 to 2016). These strategies were adopted by Advanced Accelerator Applications S.A. (France), Bayer AG (Germany), Nordion, Inc. (Canada), Eczacibasi-Monrol Nuclear Products (Turkey), Lantheus Medical Imaging (U.S.), Cardinal Health, Inc. (U.S.), IBA Molecular (France), Piramal Healthcare Limited (India), GE Healthcare (U.S.), Eckert & Ziegler Radiopharma GmbH (Germany), Mallinckrodt plc (Ireland), and Bracco Imaging S.p.A (Italy).

Related Reports:

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Contact:
Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports